Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical · Molecular biology

The landscape of peripheral blood RNA modifications and its clinical implications for diagnosis of hepatocellular carcinoma

Summary

This study investigated the landscape of RNA modifications in the peripheral blood of patients with hepatocellular carcinoma (HCC), liver cirrhosis, and healthy controls. Using liquid chromatography-tandem mass spectrometry, 55 RNA modifications were quantified, revealing 11 significantly altered modifications in HCC patients, including those at stage I. N2,N2-dimethylguanosine (m2,2G) emerged as the most profoundly dysregulated. A diagnostic model based on a panel of modifications including m2,2G, combined with IFI27 and CCR2 gene expression, demonstrated promising diagnostic performance for HCC, especially for early stages, with high AUCs. These findings suggest the potential for novel diagnostic biomarkers for HCC.

Critical appraisal

Clinical. This study provides preliminary evidence for the use of peripheral blood RNA modifications and gene expression as diagnostic biomarkers for hepatocellular carcinoma (HCC), including early-stage disease. The diagnostic model combining m2,2G, m2,2,7G, m6,6A with IFI27 and CCR2 achieved AUCs of 0.972 for overall HCC and 0.968 for stage I HCC, which is highly promising for a non-invasive screening test. These biomarkers could serve as predictive markers for early diagnosis, warranting larger-scale validation trials. If validated, this could change clinical practice by offering a more sensitive early detection method, potentially within 3 to 5 years.

Molecular biology. The discovery of 11 significantly altered RNA modifications in the peripheral blood of HCC patients, with m2,2G as a key component, represents a significant advance in understanding the molecular mechanisms of HCC. Quantification was performed using LC-MS/MS, a robust technology for RNA modification analysis. The study utilized peripheral blood samples, which is ideal for a non-invasive test. Biological validity was strengthened by in vitro (lymphocytes co-cultured with HCC cells) and in vivo (syngeneic HCC mouse model) validations, showing elevated m2,2G. The integration of IFI27 and CCR2 gene expression, measured in peripheral blood, into the multi-omics panel significantly enhances diagnostic performance, suggesting a combined role for these markers.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology